
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and …